📄 New article: Assessment of Molecular Residual Disease Using ctDNA to Identify #MultipleMyeloma Patients at High Risk of Relapse 👨‍⚕️👩‍⚕️ Binod Dhakal et al. Read here 👉 fro.ntiers.in/9BJQ Medical College of Wisconsin MCW Cancer Center #MMsm #HemOnc #Oncology #CancerPreventionMonth

Today we recruited our first patient to our new study IMvigor011 🌟 Pts are followed up after cystectomy and tested for serum ctDNA. If positive they are randomised to receive adjuvant atezo/placebo. ctDNA could be an exciting new biomarker in this cohort. Tom Powles Barts Experimental Cancer Medicine Centre

NRG-GI008 Protocol Activation! This #clinicaltrial is designed to determine whether chemotherapy is needed and if so, what kind to recommend to patients based on the presence or absence of ctDNA after surgery for #coloncancer. Read more: ow.ly/Koor50IgjSf

#JCOPO review article on how ctDNA-based MRD detection could have a major impact on the conduct of #ClinicalTrials & ultimately on the management of disease in patients w/ cancer. fal.cn/3nqu1

Adjuvant immune checkpoint inhibitor for everybody? Yes or no? Great different views from Tom Powles and VanDerHiejden. Trusting in ctDNA IMVIGOR011 recruitment to be able to reach conclusions.

Disappointed. Despite AZ, IL, LA, RI—recently passing legislation to expand access to #BiomarkerTesting, California Governor vetoed this bill #SB912, despite unanimous bipartisan support. Big step backwards for CA patients and doctors. #CallOnNewsom #ctdna genomeweb.com/policy-legisla…

In the observational arm of the CIRCULATE-Japan study, among patients with stage II-IV #ColorectalCancer, those with the presence of circulating #tumorDNA post-tumor resection have a high recurrence risk & are likely to benefit from adjuvant #chemotherapy nature.com/articles/s4159…

ctDNA testing has shown great promise in solid tumors for monitoring disease progression and detecting relapse in real time. This article reports on the use of #ctDNA testing specific to anal squamous cell carcinoma. doi.org/10.1093/oncolo…

We are pleased to announced that Merck will utilize Natera’s real-world database of de-identified clinical and genomic data from more than 100,000 early- and late-stage cancer patients who have been tested with #Signatera to advance oncology research. ow.ly/rCnI50Q7v0S

Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial buff.ly/3O6YHxr Tom Powles Zoe Assaf Petros Grivas Alexey Aleshin joaquim bellmunt Sanjeev Mariathasan

We're excited to share that we have passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting #Natera’s technology in the scientific literature. 👏natera.com/company/news/n…